


PHARMACEUTICAL 2021

Synthetic Biologics Inc. Rank 360 of 409





PHARMACEUTICAL 2021

Synthetic Biologics Inc. Rank 360 of 409

The relative strengths and weaknesses of Synthetic Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Synthetic Biologics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Synthetic Biologics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 353% points.

The company's Economic Capital Ratio, given in the ranking table, is -610%, being 256% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	7,934
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,966
Liabilities, Non-Current	186
Other Assets	302
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	44
Property and Equipment	174
Research and Development	5,131
Revenues	0
Selling, General and Administrative Expense	5,029

Output Variable	Value in 1000 USD
Assets	8,410
Liabilities	3,152
Expenses	10,160
Stockholders Equity	5,258
Net Income	-10,116
Comprehensive Net Income	-10,116
Economic Capital Ratio	-610%